TD Cowen Maintains Buy on Biodesix, Raises Price Target to $40
TD Cowen analyst Dan Brennan maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $30 to $40.
Stocks · News reference
Biodesix Affirms FY2026 Sales Guidance of $108.000M-$114.000M vs $110.996M Est
Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
Biodesix announced multiple presentations at CHEST 2026 showcasing real-world evidence for integrating Nodify Lung blood-based testing into routine lung nodule management. The presentations include sponsored research comparing biomarkers with PET imaging, independent studies on patient follow-up adherence, and analyses from the CLARIFY study involving over 2,000 patients. The company is demonstrating how blood-based biomarkers can be incorporated into structured care pathways alongside imaging.
Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management
The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects patient adherence to
Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions